PRECISE: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

Grants and Contracts Details

StatusFinished
Effective start/end date3/22/19 → 7/13/23

Funding

  • HeartFlow Incorporated: $70,036.00